PKC activation sensitizes basal-like breast cancer cell lines to Smac mimetics

L Cornmark1, C Holmgren1, K Masoumi1

  • 1Department of Laboratory Medicine, Translational Cancer Research, Lund University , Lund, Sweden.

Cell Death Discovery
|August 24, 2016
PubMed

Insights

Combining protein kinase C (PKC) activator TPA with Smac mimetic LBW242 induces cancer cell death in resistant basal breast cancer cells. This targeted approach offers potential for new basal-like breast cancer therapies.

Area of Science:

  • Molecular Oncology
  • Cancer Cell Death Induction
  • Signal Transduction Pathways

Background:

  • Novel strategies are needed to induce cancer cell death, as current treatments face resistance.
  • Smac mimetics, which target inhibitor of apoptosis proteins (IAPs), show promise in combination therapies.
  • Basal breast cancer cell lines often exhibit resistance to single-agent Smac mimetics.

Purpose of the Study:

  • To investigate the efficacy of combining a protein kinase C (PKC) activator (TPA) with a Smac mimetic (LBW242) in inducing cell death.
  • To explore the underlying molecular mechanisms, including the roles of PKC, TNFα, and NF-κB pathways.
  • To identify potential therapeutic targets for basal-like breast cancers.

Main Methods:

  • Treatment of basal breast cancer cell lines (MDA-MB-468, BT-549) with TPA and LBW242.
  • Assessment of cell death induction, PKC activity, TNFα synthesis, and caspase cleavage.
  • Analysis of RIP1/caspase-8 complex formation and NF-κB pathway activation (canonical and non-canonical).

Main Results:

  • TPA plus LBW242 induced cell death in LBW242-resistant MDA-MB-468 and BT-549 cells.
  • The effect was dependent on PKC activity and mediated by TNFα, involving caspase-3 cleavage and RIP1/caspase-8 complex formation.
  • Combined inhibition of canonical and non-canonical NF-κB pathways suppressed TNFα and cell death, suggesting a role in this combination therapy.

Conclusions:

  • Co-treatment with TPA and a Smac mimetic is a viable strategy to induce cell death in specific basal breast cancer cell lines.
  • The combination therapy leverages PKC activation, TNFα production, and caspase-dependent cell death pathways.
  • Targeting these pathways presents a promising therapeutic avenue for basal-like breast cancers.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K